Charles River acquires analytical CRO

By Melissa Fassbender

- Last updated on GMT

The acquisition is the latest in a series. (Image: iStock)
The acquisition is the latest in a series. (Image: iStock)

Related tags Charles river Executive officer Management occupations Chief executive officer

Charles River Laboratories has acquired Blue Stream Laboratories, expanding the company’s biologic and biosimilar development capabilities.

The Woburn, Massachusetts-based contract research organization (CRO) has expertise in structural and functional protein characterization programs as well as background in the development and validation of assays for current good manufacturing practice (cGMP) lot release and stability programs.

Through the acquisition, Charles River will have the ability to support biologic and biosimilar development from characterization through clinical testing and commercialization.

James C. Foster, Chairman, President and Chief Executive Officer, said that the company is continuing to invest in expanding its biologics portfolio, especially as more biologic and biosimilar drugs are in development.

The investment announced today is the latest in a series of acquisitions, coming months after it finalized its acquisition of the CDMO, WIL Research.

As previously reported​, Charles River predicted 2016 to be a “robust year,” driven mainly by customer demand and enhanced strategic partnerships. 

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Related suppliers

Follow us